<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111942</url>
  </required_header>
  <id_info>
    <org_study_id>ROB-SCCI 10-001-1</org_study_id>
    <nct_id>NCT01111942</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer</brief_title>
  <official_title>A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized open-label investigator initiated pilot study comparing follow-up
      therapy of advanced head and neck cancer subjects initially treated with triple induction
      chemotherapy. Subjects will receive surgical treatment or combined chemoradiation therapy
      based on the subject's apparent clinical response. Spared use of radiation therapy for
      selective patients who have a complete response to induction chemotherapy could improve well
      being of this patient population without compromising survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An important observation of the induction triple chemotherapy regimen know as TPF is that
      there was an unprecedented high proportion of patients treated who had a complete response of
      their disease upon the completion of the induction phase. In a recent study by Haddad, et
      al., a biopsy was performed in all patients following induction chemotherapy and before
      starting concomitant chemoradiotherapy. Patients with an incomplete response to
      chemoradiotherapy or who had N3 disease had a neck dissection 6 to 12 weeks after
      chemoradiotherapy. Twenty-nine neck dissections were performed after chemoradiotherapy. The
      neck dissection result was pathologically positive in 7 (24%) patients (all alive with no
      evidence of disease) and negative in 22 (76%) patients (21 alive with no evidence of
      disease). Post-TPF, primary site biopsy result was negative in 64 patients (89%) and positive
      in 8 patients (11%). While the protocol required all patients to subsequently receive
      concomitant chemoradiation regardless of disease response to the induction component of the
      regimen, it is reasonable to question whether the complete responder subset really needed to
      undergo the same intensive chemoradiation treatment compared to the partial responders. Thus,
      a less intense therapy may be sufficient. The long term goal of this protocol is to alter the
      model of highly effective cancer therapy from what is maximally tolerated by the patient to
      what is minimally necessary for a cure.

      One treatment strategy for patients with advanced head and neck cancer who prove to be highly
      sensitive to chemotherapy is to combine the modalities of polychemotherapy and conservation
      surgery with the goal of avoiding radiation therapy. For those patients whose primary disease
      is classified as T2-3 (resectable), and who have a complete response following induction
      therapy, it is feasible to perform an organ preservation tumor nidusectomy at the primary
      site to verify that the clinical complete response is truly pathological complete response.
      Similarly, the clinical complete response observed for the associated nodal disease, can be
      verified pathologically by performing a selective neck dissection without causing significant
      morbidity. Both tumor nidusectomy and selective neck dissection has been shown to be an
      effective adjuvant in this setting. Building on these observations, the novel protocol
      outlined in this proposal has the potential to spare the use of radiation therapy for
      selective patients who have a complete response to induction chemotherapy and thereby improve
      their well being without compromising survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathologic complete response</measure>
    <time_frame>42 months</time_frame>
    <description>To assess the rate of pathologic complete response of subjects (based on analysis of the surgical specimen), in both the primary site as well as the lymph nodes, with resectable stage III-IV squamous cell carcinoma of the oropharynx treated with TPF induction chemotherapy followed by conservation (organ preservation) surgery for clinically complete responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 year overall survival</measure>
    <time_frame>42 months</time_frame>
    <description>To assess the 2 year overall survival of subjects with resectable stage III-IV squamous cell carcinoma of the oropharynx treated with TPF induction chemotherapy followed by chemoradiation for clinically incomplete responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response</measure>
    <time_frame>42 months</time_frame>
    <description>To report the rate of clinical complete response of the local population following TPF induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year disease-free survival</measure>
    <time_frame>42 months</time_frame>
    <description>To assess the 2 year disease-free survival of both subject groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>42 months</time_frame>
    <description>Change in quality of life status at end of treatment, 1 year, and 2 year relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HPV and EGFR positivity</measure>
    <time_frame>42 months</time_frame>
    <description>To assess the incidence in both subject groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-ras mutational analysis</measure>
    <time_frame>42 months</time_frame>
    <description>To assess the incidence in both subject groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>radiation and weekly carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conservation surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radiation combined with weekly carboplatin</intervention_name>
    <description>recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;
Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.
Induction Triple Therapy Treatment with TPF:
Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)</description>
    <arm_group_label>radiation and weekly carboplatin</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>Platinol</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conservation surgery</intervention_name>
    <description>Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.</description>
    <arm_group_label>conservation surgery</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>Platinol</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent document.

          2. Histologically confirmed Stage III-IV (T1, T2, T3) (N0-N2) squamous cell carcinoma of
             the oropharynx staged according to AJCC guidelines.

          3. The subject must be considered surgically resectable via a transoral approach at the
             time of presentation.

          4. Age &gt;18 years

          5. Life expectancy &gt;/= 5 years

          6. ECOG performance status &lt;2

          7. Subject must have measurable disease, at least one lesion accurately measured in at
             least one dimension as &gt;10 mm with CT scan.

          8. Hematologic Absolute neutrophil count &gt; 1,000/mm3, Hemoglobin &gt; 8.0 g/dl Platelet
             count &gt; 100,000/mm3 Leukocytes &gt;3,000/mcL

          9. Hepatic Total Bilirubin â‰¤ ULN; AST and ALT and Alkaline Phosphatase within the
             eligible range

         10. Renal - creatinine within normal institutional limits or &gt;60 mL/min/1.73 m2 creatinine
             &gt; institutional normal

         11. Women of childbearing potential with negative pregnancy test.

         12. Men and women of childbearing age willing to use effective contraception

        Exclusion Criteria:

          1. N3 nodal disease according to AJCC guidelines

          2. Retropharyngeal nodal involvement

          3. Trismus

          4. Second primary head and neck tumor unless it is/was a basal or squamous cell skin
             cancer

          5. Prior surgery, chemotherapy, biologic or radiotherapy for a head or neck malignancy

          6. Concurrent investigational agent or intervention (within 90 days of screening visit)

          7. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to docetaxol, cisplatin, 5- fluorouracil, or carboplatin.

          8. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80

          9. Breastfeeding women

         10. Pre-existing peripheral neuropathy grade &gt; 3

         11. Evidence of distant metastatic disease

         12. Unknown primary site

         13. Prior or concurrent malignancies (excluding adequately treated basal or squamous cell
             skin cancer, in situ cervical cancer, stage I or II cancer from which the subject has
             been in complete remission for at least 12 months (excluding head and neck), any
             cancer from which the subject has been cancer free for 5 years)

         14. History of allergies to any of the pre-medications.

         15. Investigator consideration based upon screening interview and/or procedures

         16. Evidence of bone invasion/destruction

         17. Uncontrolled intercurrent illness including ongoing or active infection, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements

         18. Pregnant women

         19. History of HIV, hepatitis B, hepatitis C, or delta antigen

         20. Known allergy to India Ink or methylene blue
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. T. Robbins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krishna Rao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siumed.edu/cancer/trials/trials_main.html</url>
    <description>SimmonsCooper Cancer Institute at SIU; clinical trials webpage</description>
  </link>
  <reference>
    <citation>Robbins KT, Howell SB, Williams JS. Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer. 2010 May 1;116(9):2068-70. doi: 10.1002/cncr.24930.</citation>
    <PMID>20186833</PMID>
  </reference>
  <reference>
    <citation>Malone J, Robbins KT. Neck dissection after chemoradiation for carcinoma of the upper aerodigestive tract: indications and complications. Curr Opin Otolaryngol Head Neck Surg. 2010 Apr;18(2):89-94. doi: 10.1097/MOO.0b013e32833693e7. Review.</citation>
    <PMID>20125024</PMID>
  </reference>
  <reference>
    <citation>Malone JP, Gerberi MA, Vasireddy S, Hughes LF, Rao K, Shevlin B, Kuhn M, Collette D, Tennenhouse J, Robbins KT. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1119-25. doi: 10.1001/archoto.2009.152.</citation>
    <PMID>19917925</PMID>
  </reference>
  <reference>
    <citation>Rogers LQ, Rao K, Malone J, Kandula P, Ronen O, Markwell SJ, Courneya KS, Robbins KT. Factors associated with quality of life in outpatients with head and neck cancer 6 months after diagnosis. Head Neck. 2009 Sep;31(9):1207-14. doi: 10.1002/hed.21084.</citation>
    <PMID>19360748</PMID>
  </reference>
  <reference>
    <citation>Robbins KT, Homma A. Intra-arterial chemotherapy for head and neck cancer: experiences from three continents. Surg Oncol Clin N Am. 2008 Oct;17(4):919-33, xi. doi: 10.1016/j.soc.2008.04.015. Review.</citation>
    <PMID>18722926</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

